TAK Quote, Financials, Valuation and Earnings

Daiichi Sankyo has a net margin of -9.79% compared to Takeda Pharmaceutical's net margin of 12.77%. Takeda Pharmaceutical's return on equity of 1.49% beat Daiichi Sankyo's return on equity of 17.67%.

Takeda Pharmaceutical has a consensus price target of $17.15, signalling upside risk potential of 12.32%. On the other hand Daiichi Sankyo has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than Daiichi Sankyo, analysts believe Takeda Pharmaceutical is more attractive than Daiichi Sankyo.

Takeda Pharmaceutical has a beta of 0.227, which suggesting that the stock is 77.347% less volatile than S&P 500. In comparison Daiichi Sankyo has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.115%.

Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.02%. Daiichi Sankyo offers a yield of 1.57% to investors and pays a quarterly dividend of $0.20 per share. Takeda Pharmaceutical pays 280.28% of its earnings as a dividend. Daiichi Sankyo pays out 38.65% of its earnings as a dividend. Daiichi Sankyo's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical's is not.

Takeda Pharmaceutical quarterly revenues are $6.9B, which are larger than Daiichi Sankyo quarterly revenues of $3.2B. Takeda Pharmaceutical's net income of -$676.5M is lower than Daiichi Sankyo's net income of $406M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 70.53x while Daiichi Sankyo's PE ratio is 23.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.65x versus 3.73x for Daiichi Sankyo. Usually stocks with elevated PS ratios are considered overvalued.

Healios KK has a net margin of -9.79% compared to Takeda Pharmaceutical's net margin of -6742.11%. Takeda Pharmaceutical's return on equity of 1.49% beat Healios KK's return on equity of -196.15%.

Takeda Pharmaceutical has a consensus price target of $17.15, signalling upside risk potential of 12.32%. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than Healios KK, analysts believe Takeda Pharmaceutical is more attractive than Healios KK.

Takeda Pharmaceutical has a beta of 0.227, which suggesting that the stock is 77.347% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.02%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 280.28% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend.

Takeda Pharmaceutical quarterly revenues are $6.9B, which are larger than Healios KK quarterly revenues of $249.2K. Takeda Pharmaceutical's net income of -$676.5M is lower than Healios KK's net income of -$16.8M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 70.53x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.65x versus 76.64x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.

PeptiDream has a net margin of -9.79% compared to Takeda Pharmaceutical's net margin of -24.41%. Takeda Pharmaceutical's return on equity of 1.49% beat PeptiDream's return on equity of 34.1%.

Takeda Pharmaceutical has a consensus price target of $17.15, signalling upside risk potential of 12.32%. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than PeptiDream, analysts believe Takeda Pharmaceutical is more attractive than PeptiDream.

Takeda Pharmaceutical has a beta of 0.227, which suggesting that the stock is 77.347% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.542, suggesting its less volatile than the S&P 500 by 45.756%.

Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.02%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 280.28% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend.

Takeda Pharmaceutical quarterly revenues are $6.9B, which are larger than PeptiDream quarterly revenues of $27.8M. Takeda Pharmaceutical's net income of -$676.5M is lower than PeptiDream's net income of -$6.8M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 70.53x while PeptiDream's PE ratio is 14.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.65x versus 5.17x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

Nxera Pharma has a net margin of -9.79% compared to Takeda Pharmaceutical's net margin of -11.44%. Takeda Pharmaceutical's return on equity of 1.49% beat Nxera Pharma's return on equity of -8.65%.

Takeda Pharmaceutical has a consensus price target of $17.15, signalling upside risk potential of 12.32%. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Takeda Pharmaceutical has higher upside potential than Nxera Pharma, analysts believe Takeda Pharmaceutical is more attractive than Nxera Pharma.

Takeda Pharmaceutical has a beta of 0.227, which suggesting that the stock is 77.347% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.360, suggesting its less volatile than the S&P 500 by 64.028%.

Takeda Pharmaceutical has a quarterly dividend of $0.33 per share corresponding to a yield of 4.02%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Takeda Pharmaceutical pays 280.28% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend.

Takeda Pharmaceutical quarterly revenues are $6.9B, which are larger than Nxera Pharma quarterly revenues of $43.6M. Takeda Pharmaceutical's net income of -$676.5M is lower than Nxera Pharma's net income of -$5M. Notably, Takeda Pharmaceutical's price-to-earnings ratio is 70.53x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Takeda Pharmaceutical is 1.65x versus 3.51x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.